Skip to Main Content

Paper Details

AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling.
Mol Cancer Res
9
2021
-Catenin, AKT, AKT isoforms, AKT1, AKT1 E17K, AKT1 E17K mutation, AKT1 E17K-mutant isogenic system, AKT2, CDH1, CDH1 mutations, Cancer, Cancer Cell, E, E-cadherin, E17K, PI3K, PIK3CA, PIK3CA mutation, PTEN, TP53, ZEB1, breast cancer, breast tumors, cancers, catenin, endogenous promoter, epithelial, human, of -catenin, patients
Author NameAffiliation
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Barry S TaylorWeill Medical College of Cornell University
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Barry S TaylorWeill Medical College of Cornell University
  • 1 - 10

Datasets

Release 1.2